Effect of selenium supplementation on lipid profile in hemodialysis patients

Introduction: one of the major causes of mortality in chronic kidney disease (ckd) patients on hemodialysis is premature atherosclerosis. selenium, a trace element involved in important enzymatic activities inside the body, has protective effects against lipid oxidation and inhibits cholesterol accumulation in blood vessels.objectives: to determine the effect of selenium supplementation on lipid profile in hemodialysis patients.patients and methods: in this double-blinded randomized clinical trial which lasted for 3 months, 84 hemodialysis patients with selenium deficiency were divided into experimental group (received selenium supplementation) or control group (received placebo). total cholesterol, low-density lipoprotein (ldl-c), high-density lipoprotein (hdl-c), blood urea nitrogen (bun), creatinine, and selenium level were measured before and after the study.results: mean (±sd) serum ldl-c level significantly increased in experimental group from 85.66 (±31.12) to 109.12 (±32.29) mg/dl (p < 0.001). likewise, in control group serum ldl-c significantly increased from 80.55 (±21.13) to 97.05 (±28.07) mg/dl (p < 0.001). however, with control of ldl-c effect before and after the study, it was revealed that ldl-c change was not statistically significant (p = 0.21). similarly, total cholesterol and triglyceride levels did not show significant changes before and after the study in any group.conclusion: selenium supplementation had no beneficial effect on lipid profile in hemodialysis patients.